Gastroesophageal Reflux Disease (GERD) Device Market : Global Industry Analysis and Opportunity Assessment, 2036

Gastroesophageal Reflux Disease (GERD) Device Market Size, Market Forecast and Outlook By FMI

The gastroesophageal reflux disease device market was valued at USD 1.3 billion in 2025. The market is set to reach USD 1.3 billion by 2026-end and expand at a CAGR of 3.9% between 2026 and 2036 to reach USD 1.9 billion by 2036. Hospitals are expected to dominate with a 60.0% end-user share, and direct sales are estimated to lead the distribution channel segment with a 58.0% share.

Summary of the Gastroesophageal Reflux Disease Device Market

• Demand and Growth Drivers
  • Reflux confirmation needs create steady demand for diagnostic devices as physicians need evidence before advanced treatment decisions.
  • Endoscopy use strengthens product demand as persistent symptoms often require direct esophageal review before procedure planning.
  • Procedure-based care expands carefully as selected patients move from medicine to device-assisted reflux management.
• Product and Segment View
  • Esophagoscopes and gastroscopes are expected to lead the product type segment with 42.0% share in 2026, reflecting first-line diagnostic use.
  • Fundoplication procedures are expected to lead procedure demand with 35.0% share in 2026, reflecting use in refractory cases.
  • Hospitals are expected to lead end-user demand with 60.0% share in 2026, reflecting equipment access and trained clinical teams.
• Geography and Competitive Outlook
  • USA is expected to record a CAGR of 5.2% through 2036 as reflux testing and procedure access expand.
  • India is projected to expand at 4.5% CAGR by 2036, as hospital endoscopy capacity improves.
  • Companies combining endoscopy platforms with reflux testing and procedure training are strengthening their market position.
• Analyst Opinion
  • Anurag Sharma, Principal Consultant for the healthcare domain at FMI, says, “GERD device demand is an extension of reflux care instead of a medicine substitute. Use builds after persistent symptoms and stronger proof from endoscopy or pH monitoring. Implantable therapy faces cost pressure as hospitals review procedure volume and training burden.”
• Gastroesophageal Reflux Disease Device Market Value Analysis
  • The gastroesophageal reflux disease device market is moving from broad reflux diagnosis into a more structured diagnostic and treatment device base.
  • Adoption improves with the need for reflux confirmation before fundoplication and sphincter augmentation procedures.
  • The market benefits from deeper use of esophagoscopes and gastroscopes across persistent reflux evaluation.
  • Hospitals carry demand by needing imaging systems and testing platforms to deliver integrated diagnostic and treatment capabilities within a single environment.

Gastroesophageal Reflux Disease Device Market Definition

The gastroesophageal reflux disease device market includes diagnostic and treatment devices used to evaluate or manage chronic reflux disease. Products include esophagoscopes, gastroscopes, manometry systems, pH monitoring systems, fundoplication devices, sphincter augmentation devices, and radiofrequency ablation devices. Scope excludes reflux medicines, over-the-counter antacids, lifestyle programs, and general hospital equipment without GERD-specific use.

Gastroesophageal Reflux Disease Device Market Inclusions

Market scope covers all commercially traded gastroesophageal reflux disease device products categorized by product type, including esophagoscopes and gastroscopes, diagnostic devices, manometry systems, pH monitoring systems, treatment devices, fundoplication devices, sphincter augmentation devices, and radiofrequency ablation devices. Scope also covers procedures including diagnostic procedures, fundoplication procedures, radiofrequency thermal ablation, and magnetic sphincter augmentation.

End users include hospitals, diagnostic centers, and ambulatory surgical centers, while technologies include minimally invasive, endoscopic, implantable, and energy-based systems. Revenue scope covers 2026 to 2036. Stakeholders include GERD device manufacturers, endoscopy system suppliers, reflux testing platform providers, hospitals, gastroenterology departments, diagnostic centers, ambulatory surgical centers, distributors, service providers, regulatory bodies, and healthcare payers.

Gastroesophageal Reflux Disease Device Market Exclusions

Scope does not include acid-suppressing medicines, antacids, diet therapy, hospital consulting services, or general gastrointestinal devices without GERD application.

Gastroesophageal Reflux Disease Device Market Research Methodology

• Primary Research: FMI analysts reviewed inputs from hospitals, diagnostic centers, gastroenterology departments, device makers, and distribution partners in major markets.
• Desk Research: FMI combined data from clinical references, regulatory pathways, public product portfolios, and adjacent device areas such as manometry system demand.
• Market sizing and forecasting: FMI added device use across diagnostic procedures and treatment procedures from the bottom up.
• Data validation: FMI cross-checked every three months against procedure mix, country-level access, and company portfolio coverage.

Why is the Gastroesophageal Reflux Disease Device Market Growing?

• Physicians are using reflux testing earlier as symptom overlap can lead to uncertain treatment decisions.
• Hospitals are upgrading upper GI imaging as esophageal review stays central to persistent symptom evaluation.
• Selected refractory patients create procedure demand for fundoplication and sphincter augmentation devices.

Reflux testing demand reflects the need to separate acid reflux from similar throat or chest symptoms. In September 2024, the American College of Gastroenterology reported that wireless pH monitoring produced 50% diagnostic yield for GER-positive cases compared with 27% for 24-hour impedance monitoring. The difference raises the value of patient-friendly pH platforms as physicians seek stronger proof before procedure referral. Device suppliers with reliable monitoring formats can help hospitals reduce repeat testing and improve case selection.

Device use is expanding through a larger global device base that requires clearer classification and clinical control. WHO states that about 2 million types of medical devices are available worldwide across over 7,000 generic device groups. The large device pool increases the need for defined clinical use pathways across GERD diagnosis and treatment. GERD device companies gain an advantage if product claims, training, and follow-up align with real hospital workflows.

Market Segmentation Analysis

• Esophagoscopes and gastroscopes are estimated to represent 42.0% of product type revenue in 2026 as upper GI review guides reflux assessment.
• Fundoplication procedures are projected to capture 35.0% share of procedures during 2026, supported by refractory GERD cases requiring anatomical correction.
• Hospital settings are expected to generate 60.0% end-user share for 2026 through combined diagnosis and treatment planning capabilities.
• Minimally invasive technology is anticipated to hold 45.0% technology share by 2026 as eligible patients favor lower procedural burden and faster recovery.
• Direct sales are forecast to cover 58.0% channel share in 2026, reflecting account-managed purchasing across large hospital systems.

The market for gastroesophageal reflux disease devices is divided into five primary segment groups based on product type, procedure, end user, technology, and distribution channel. Product type includes esophagoscopes and gastroscopes, diagnostic devices, manometry systems, pH monitoring systems, treatment devices, ultrasonic surgical endostaplers, fundoplication devices, sphincter augmentation devices, and radiofrequency ablation devices. Procedure includes diagnostic procedures, fundoplication procedures, radiofrequency thermal ablation, and magnetic sphincter augmentation. End user includes hospitals, diagnostic centers, and ambulatory surgical centers. Technology includes minimally invasive technology, endoscopic technology, implantable technology, and energy-based technology. Distribution channel includes direct sales, distributors, and online channels.

Insights into Gastroesophageal Reflux Disease Device Market by Product Type

• In 2026, esophagoscopes and gastroscopes are expected to make up 42.0% of the product type segment. Upper GI visualization supports reflux assessment across patients needing esophageal review and treatment direction.
• Diagnostic devices address functional testing needs after visual review. Their value improves in unclear reflux cases requiring pH monitoring and motility assessment.

Insights into Gastroesophageal Reflux Disease Device Market by Procedure

• Fundoplication procedures are projected to account for 35.0% of the procedure segment in 2026. Refractory GERD cases require anatomical reflux control after medicine and diagnostic evaluation fall short.
• Radiofrequency thermal ablation and magnetic sphincter augmentation address selected treatment needs. Their use improves across centers with stronger patient selection and physician training.

Insights into Gastroesophageal Reflux Disease Device Market by End User

• Hospitals are estimated to account for 60.0% share in 2026. Hospital settings carry higher device value through endoscopy rooms and trained gastrointestinal care teams.
• Diagnostic centers support reflux evaluation through testing and imaging services. Ambulatory surgical centers serve selected minimally invasive procedures requiring faster patient discharge.

Insights into Gastroesophageal Reflux Disease Device Market by Technology

• Minimally invasive technology is forecast to represent 45.0% share in 2026. Patients and clinicians prefer lower incision burden and shorter recovery across eligible reflux procedures.
• Endoscopic and implantable technologies support advanced GERD treatment needs. Device choice varies by reflux severity and physician confidence in patient selection.

Insights into Gastroesophageal Reflux Disease Device Market by Distribution Channel

• Direct sales are projected to hold 58.0% share in 2026. Large hospital buyers prefer direct sourcing for training coverage and service coordination.
• Distributor sales support smaller facilities requiring faster product access. Online channels serve limited device ordering needs for repeat purchases and standard supplies.

Gastroesophageal Reflux Disease Device Market Drivers, Restraints, and Opportunities

• Objective reflux confirmation raises device demand as treatment decisions need pH testing and endoscopy evidence.
• High procedure cost enhances restraint as implantable systems need trained surgeons and sufficient case flow.
• Patient-friendly diagnostics improve opportunity as wireless pH testing can improve comfort and test completion.

Gastroesophageal reflux disease device systems see steady use as hospitals need reliable reflux testing and procedure tools for patients with persistent symptoms. Cost pressure and specialist training needs can slow broader use of implantable and energy-based treatment devices. Use continues across upper GI endoscopy systems and pH monitoring platforms as healthcare demand favors sustained adoption across diagnostic and treatment pathways. Demand continues in minimally invasive reflux procedures as providers seek effective treatment options with faster recovery and improved patient outcomes.

CMS Outpatient Updates Put a Ceiling on Device Price Hikes

GERD device pricing faces tighter outpatient reimbursement economics beyond broad medtech inflation. In November 2025, CMS finalized a 2.6% CY 2026 payment update for both hospital outpatient departments and ASCs, affecting about 4,000 hospitals and 6,000 ASCs. For GERD diagnostics and intervention-related devices, including pH monitoring systems and manometry platforms, the update creates limited room for list price increases. Endoscopic accessories and anti-reflux procedure tools face pricing pressure as cautious capital spending across healthcare providers. Suppliers may find stronger acceptance for service contracts and utilization-based pricing to improve revenue stability under constrained budgets. Suppliers may promote bundled maintenance over aggressive capital pricing because provider budgets are rising modestly and purchasing scrutiny is high.

ASC Endoscopy Cuts Pressure GERD Device Margins

Pricing pressure is sharper in ASC-based GERD care because procedure economics are being reset downward. The American Gastroenterological Association reported in November 2025 that, as of January 1, 2026, Medicare cut payments for GI endoscopy services performed in ASCs by an average of 8%. The cut affects GERD devices because endoscopy-adjacent diagnostics and minimally invasive anti-reflux technologies rely on procedure profitability at the site of care. ASC operators may resist premium consumable pricing, delay capital upgrades, and favor vendors that reduce per-case cost. Device companies may need to defend price through shorter procedure time and strong coding support to show clear clinical and economic value. Vendors can use warranty coverage and measurable throughput gains to strengthen pricing justification and improve customer acceptance.

Analysis of Gastroesophageal Reflux Disease Device Market By Key Countries

Country	CAGR
USA	5.2%
India	4.5%
China	3.6%
Brazil	3.2%
France	2.1%
Germany	2.0%
UK	1.6%

Source: Future Market Insights, 2026.

Gastroesophageal Reflux Disease Device Market CAGR Analysis By Country

• USA records the highest country outlook at 5.2% CAGR through 2036, helped by broader reflux testing access and stronger procedure availability.
• India is projected at 4.5% CAGR, with hospital endoscopy capacity improving across major private care networks.
• China’s 3.6% CAGR points to steady device demand from hospital diagnostics and tighter medical device standards.
• Brazil advances at 3.2% CAGR over the forecast period, with private hospital investment and more disciplined device registration pathways.
• France is forecast at 2.1% CAGR through 2036, with mature device use keeping expansion measured across reflux procedures.
• Germany’s 2.0% CAGR through 2036 indicates a stable market shaped by established medical technology infrastructure and slower replacement timing.
• UK demand is expected to rise at 1.6% CAGR by 2036, limited by budget pressure and selective upgrades for procedure devices.

Demand for gastroesophageal reflux disease devices is forecast to rise at 3.9% CAGR from 2026 to 2036. Country-level analysis covers the major markets contributing to this forecast, with the country markets listed below.

Demand Outlook for Gastroesophageal Reflux Disease Device Market in the USA

The USA gastroesophageal reflux disease device industry is projected to record a CAGR of 5.2% through 2036. In 2025, NIDDK reported about 20% of people in the United States have GERD. The symptom base strengthens demand for U.S. reflux diagnosis and selected device-assisted treatment. Hospitals and GI practices need systems to reduce uncertainty before procedure referral.

• Strong reflux burden favors demand for pH monitoring and upper GI endoscopy.
• Advanced procedure access makes space for magnetic sphincter augmentation and fundoplication systems.
• Hospital buyers value device platforms with service coverage and clinical training.

Sales Analysis of Gastroesophageal Reflux Disease Device Market in India

India’s gastroesophageal reflux disease device sector is expected to expand at a CAGR of 4.5% during the assessment period. India’s medical device base improves through domestic production programs and hospital equipment demand. The Press Information Bureau reported in January 2026 that cumulative sales under a medical device scheme reached ₹2,315.44 crore as of September 2025. The production base improves access to device infrastructure across large care centers.

• Hospital expansion raises demand for gastroscopes and reflux monitoring tools.
• Domestic device sales create stronger availability for adjacent GI diagnostic systems.
• Private hospitals need trained service partners for endoscopy platform uptime.

Demand Outlook for Gastroesophageal Reflux Disease Device Market in China

China’s gastroesophageal reflux disease device industry is forecast to grow at 3.6% CAGR by 2036. The regulatory base in the country has become more structured for medical devices. NMPA reported in May 2024 that it approved and released 131 industry standard projects for medical devices. The standards activity improves device quality expectations across hospital purchasing.

• Hospital GI departments need devices aligned with technical standards and safety controls.
• Local purchasing favors suppliers with clear filing records and training capability.
• Endoscopy platform demand benefits from large urban hospital networks.

Opportunity Analysis of Gastroesophageal Reflux Disease Device Market in Brazil

The gastroesophageal reflux disease device segment in Brazil is forecast to advance at 3.2% CAGR over the forecast years. Brazil’s regulator is strengthening device traceability and registration controls. ANVISA reported in July 2025 that all risk class IV devices made from July 10, 2025 must carry unique identification. The rule improves traceability expectations for higher-risk device categories.

• Private hospitals increase the main demand base for advanced GERD procedure systems.
• Traceability rules increase the value of compliant suppliers and clear documentation.
• Imported device access is important for advanced reflux treatment platforms.

Future Outlook for Gastroesophageal Reflux Disease Device Market in France

France’s gastroesophageal reflux disease device industry is expected to post 2.1% CAGR through 2036. France has a mature medical device base with steady replacement demand. Trade.gov reported in August 2024 that France’s medical device turnover was estimated at €37.4 billion for 2023. Mature market size supports device availability. Reimbursement discipline limits faster expansion.

• Mature hospitals drive replacement demand for gastroscopes and reflux testing systems.
• Reimbursement review keeps advanced GERD procedure use selective.
• Suppliers need clinical evidence and service reliability to protect hospital contracts.

Demand Outlook for Gastroesophageal Reflux Disease Device Market in Germany

Germany’s gastroesophageal reflux disease device industry is forecast to grow at 2.0% CAGR through 2036. Germany has one of Europe’s strongest medical technology bases. As per the Trade.gov statement from August 2025, Germany’s medical device market accounts for roughly USD 44 billion in annual revenue. The strong base supports device availability. Mature hospital networks replace systems carefully.

• Established GI care increases steady use of endoscopy and reflux testing platforms.
• Mature hospital purchasing raises slower upgrade timing for procedure systems.
• Suppliers with service depth can defend share in account-based sales.

In-depth Analysis of Gastroesophageal Reflux Disease Device Market in the UK

The UK gastroesophageal reflux disease device industry is expected to expand at 1.6% CAGR through 2036. Budget control and planned care pressure influence device upgrades across NHS pathways. GOV.UK reported in October 2025 that the medical technology subsector generated £48.0 billion in turnover during 2023 to 2024. The industrial base is strong. GERD device uptake is selective across advanced procedures.

• NHS capacity pressure favors diagnostic tools with efficient patient flow.
• Private providers improve demand for selected reflux treatment systems.
• Device suppliers need evidence packages to fit pathway and budget reviews.

Competitive Landscape and Strategic Positioning

Gastroesophageal Reflux Disease Device Market Analysis By Company

• Olympus Corporation competes from a strong upper GI imaging base across hospital endoscopy departments and reflux assessment programs.
• Fujifilm Holdings Corporation and PENTAX Medical compete through imaging platforms and repair networks across major clinical markets.
• Specialist reflux companies focus on esophageal catheters and pH monitoring systems for patients needing functional reflux assessment.

Competitive activity in the gastroesophageal reflux disease device market centers on upper GI imaging and reflux testing platforms. Procedure system providers compete through patient selection evidence and physician training depth across advanced GERD treatment programs. Olympus Corporation holds a strong position through broad endoscopy platform coverage across hospital GI units. Fujifilm Holdings Corporation offers endoscopy video systems and repair coverage across major country markets. PENTAX Medical and KARL STORZ compete through upper GI visualization and procedure tools. Johnson & Johnson MedTech and Merit Medical serve treatment demand through LINX and EsophyX Z+ systems.

Adoption barriers include surgeon training requirements and evidence expectations across advanced GERD treatment. Supplier priorities center on image quality and patient-friendly reflux testing across hospital purchasing decisions. Buyers prefer suppliers combining dependable devices with training coverage and practical follow-up service. Companies with strong hospital account access and responsive service teams are well placed to win GERD device contracts.

Key Companies in the Gastroesophageal Reflux Disease Device Market

Global companies active in the gastroesophageal reflux disease device market include:

• Olympus Corporation, Fujifilm Holdings Corporation, and PENTAX Medical have strong endoscopy infrastructure for upper GI diagnosis and visualization.
• KARL STORZ, Johnson & Johnson MedTech, and Merit Medical Systems serve procedure-focused demand across minimally invasive GERD treatment.
• LABORIE and Diversatek hold specialist positions across reflux monitoring and motility testing systems.

Competitive Benchmarking: Gastroesophageal Reflux Disease Device Market

Company	Upper GI Imaging Depth	Reflux Testing Coverage	Antireflux Procedure Presence	Geographic Footprint
Olympus Corporation	High	Low	Low	Global, with strong Japan, North America, Europe, and Asia Pacific coverage
Fujifilm Holdings Corporation	High	Low	Low	Global, with strong Japan, USA, Europe, and Asia Pacific coverage
PENTAX Medical	High	Low	Low	Global, with offices across Asia, Europe, the Americas, Middle East, and Africa
KARL STORZ SE & Co KG	Medium	Low	Medium	Global, with over 70 subsidiaries in over 50 countries
Johnson & Johnson MedTech	Low	Low	High	Global, with North America, Asia Pacific, EMEA, and Latin America coverage
Merit Medical Systems	Low	Low	High	Global, with strong USA, Europe, and Asia Pacific presence
LABORIE	Low	High	Low	Global, with offices and distributors across North America, Europe, and Asia Pacific
Diversatek	Low	High	Low	Select international footprint, with USA base and locations in Vietnam and Belgium

Source: Future Market Insights, 2026.

Key Developments in Gastroesophageal Reflux Disease Device Market

• In August 2024, Johnson & Johnson MedTech announced U.S. Food and Drug Administration approval of a LINX label update for GERD patients with Barrett’s esophagus.
• In July 2024, Merit Medical Systems signed an asset purchase agreement with EndoGastric Solutions for approximately USD 105 million.
• In October 2025, Fujifilm launched the ELUXEO 8000 endoscopic imaging system with seven U.S. Food and Drug Administration 510(k)-cleared 800 Series endoscopes.

Key Players in the Gastroesophageal Reflux Disease Device Market

Major Global Players

• Olympus Corporation
• Fujifilm Holdings Corporation
• PENTAX Medical
• KARL STORZ SE & Co KG
• Johnson & Johnson MedTech
• Merit Medical Systems

Specialist Players

• LABORIE
• Diversatek
• Mederi Therapeutics

Report Scope and Coverage

Gastroesophageal Reflux Disease Device Market Breakdown By Product Type, Procedure, End User, Technology, Distribution Channel, And Region

Parameter	Details
Quantitative Units	USD 1.3 billion to USD 1.9 billion, at a CAGR of 3.9%
Market Definition	The GERD device market covers diagnostic and treatment devices used for reflux evaluation and device-assisted care.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, India, China, Brazil, France, Germany, UK, and 30+ countries
Key Companies Profiled	Olympus Corporation, Fujifilm Holdings Corporation, PENTAX Medical, KARL STORZ, Johnson & Johnson MedTech, Merit Medical, LABORIE, Diversatek
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with procedure demand and verified product use patterns.

Gastroesophageal Reflux Disease Device Market by Segments

Gastroesophageal Reflux Disease Device Market Segmented by Product Type:

• Esophagoscopes and Gastroscopes
• Diagnostic Devices
• Manometry Systems
• pH Monitoring Systems
• Treatment Devices
• Ultrasonic Surgical Endostaplers
• Fundoplication Devices
• Sphincter Augmentation Devices
• Radiofrequency Ablation Devices

Gastroesophageal Reflux Disease Device Market Segmented by Procedure:

• Diagnostic Procedures
• Fundoplication Procedures
• Radiofrequency Thermal Ablation
• Magnetic Sphincter Augmentation

Gastroesophageal Reflux Disease Device Market Segmented by End User:

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers

Gastroesophageal Reflux Disease Device Market Segmented by Technology:

• Minimally Invasive Technology
• Endoscopic Technology
• Implantable Technology
• Energy-based Technology

Gastroesophageal Reflux Disease Device Market Segmented by Distribution Channel:

• Direct Sales
• Distributors
• Online Channel

Gastroesophageal Reflux Disease Device Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Rest of Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East and Africa
  • Saudi Arabia
  • Other GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Research Sources and Bibliography

1. American Gastroenterological Association. (2025, November 6). Five ways for independent GI practices to mitigate the impact of payment cuts. AGA.
2. Centers for Medicare & Medicaid Services. (2025, November 21). Calendar Year 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Final Rule (CMS-1834-FC). CMS.
3. National Institute of Diabetes and Digestive and Kidney Diseases. (2025, October). Definition and facts for GER and GERD. NIDDK.
4. American College of Gastroenterology. (2024, September). Diagnostic yield of prolonged wireless pH vs 24-hour pH impedance monitoring. ACG.
5. Press Information Bureau. (2026, January). India MedTech Expo 2025 showcased end-to-end capabilities of India’s medical devices sector. Government of India.
6. National Medical Products Administration. (2024, May). China Medical Device Standards Management Annual Report. NMPA.
7. Agência Nacional de Vigilância Sanitária. (2025, July). Identificação Única de Dispositivos Médicos: próximas etapas de implementação. ANVISA.
8. International Trade Administration. (2024, August). France medical devices. U.S. Department of Commerce.
9. International Trade Administration. (2025, August). Germany healthcare and medical technology. U.S. Department of Commerce.
10. Department for Science, Innovation and Technology. (2025, October). Bioscience and health technology sector statistics 2023 to 2024. GOV.UK.
11. Johnson & Johnson MedTech. (2024, August). Johnson & Johnson MedTech announces labeling amendment of LINX Reflux Management System in the U.S.
12. Merit Medical Systems. (2024, July). Merit Medical announces asset purchase agreement with EndoGastric Solutions Inc.
13. Fujifilm. (2025, October). Fujifilm launches next-generation ELUXEO endoscopic imaging system.

This Report Answers

• What is the current and future size of the gastroesophageal reflux disease device market?
• How fast is the gastroesophageal reflux disease device market expected to expand between 2026 and 2036?
• Which product type is expected to lead the market by 2026?
• Which end-user segment is expected to account for the highest demand by 2026?
• What factors are driving demand for gastroesophageal reflux disease devices globally?
• How are reflux testing needs influencing adoption of diagnostic devices?
• Why are hospitals the main demand base for GERD device systems?
• How are minimally invasive procedures creating demand for advanced reflux devices?
• Which countries are projected to record faster expansion through 2036?
• What is driving market expansion in USA and India?
• Who are the key companies active in the gastroesophageal reflux disease device market?
• How does FMI estimate and validate the market forecast?